$0.81
+0.35 (+74.89%)
Open$0.61
Previous Close$0.46
Day High$1.13
Day Low$0.58
52W High$5.33
52W Low$0.40
Volume—
Avg Volume1.07M
Market Cap22.86M
P/E Ratio—
EPS$-1.00
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+2,281.2% upside
Current
$0.81
$0.81
Target
$19.24
$19.24
$16.83
$19.24 avg
$29.48
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 61.09M | 42.78M | 27.35M |
| Net Income | -18,983,106 | -11,964,980 | 6.20M |
| Profit Margin | -31.1% | -29.5% | 22.7% |
| EBITDA | -3,505,748 | -2,332,418 | 9.44M |
| Free Cash Flow | — | — | 4.10M |
| Rev Growth | +42.8% | +42.8% | -0.5% |
| Debt/Equity | 4.00 | 4.00 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $258.92 | +3.43% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $425.28 | +1.41% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $143.44 | +3.25% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $528.19 | +2.45% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $810.24 | +0.53% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.61 | +1.79% | 37.6 | 30.39B |